Warps I as well as many others would be more than thrilled if AMBS can pull the proverbial rabbit out of the hat by demonstrating some measure of revenue recognition. IMHO, to continue down the road of equity distribution without revenue is simply not pragmatic business practice - especially given Amarantus start-up status. With any kind of savvy BOA/BOD guidance, the new acquisition in play per today's PR and Dominion's $3-Mil. tranche is already cash flow positive. Let's hope so - for everyone's sake. What could sooth the restless savage souls would be LymPro revenue guidance given by Dr. Rubenfeld himself. The Street would most certainly welcome this.